Search

Albany Molecular Research Inc. made two risky acquisitions in 2010 and it faced challenges later in the year including a warning letter from the FDA and an unfavorable ruling. Albany's CEO Thomas E. D'Ambra discusses the way forward for the company.

The two important problems affecting drug discovery company, Albany Molecular Research Inc. relating to the softening of its growth, and keeping in pace the demands; the company net profits for the year 2004 and its acquisition of the Rensselaer based drug manufacturer Organichem, are discussed.

ALBANY MOLECULAR Research Inc. (AMRI) will acquire two pharmaceutical manufacturing sites in India from Runwal Group for about $11m in cash. The deal, expected to close during the second or [...]

IN A MOVE to facilitate the optimization and scale-up of discoveries made in combinatorial biocatalysis and natural products chemistry, Albany Molecular Research Inc. (AMRI) has purchased Great Lakes Chemical Corp.'s [...]

Albany Molecular Research Inc. signed an agreement to purchase Great Lakes Chemical Corp.'s laboratory facilities in Mt. Prospect, Ill., for $10 million in cash. The site includes chemistry synthesis labs, [...]

Albany Molecular Research has purchased Great Lakes Chemical's laboratory facilities at Mt. Prospect, IL for $10 million. The site includes a chemistry synthesis lab, a non-cGMP pilot plant, and research [...]

Two recent acquisitions involving local companies help show where the biotechnology industry is focused in 2001: late-stage drug development. Seattle-based Corixa Corp.'s acquisition of South San Francisco-based Coulter Pharmaceutical added [...]

ALBANY MOLECULAR Research Incorporated (AMRI) has completed the acquisition of New Chemical Entities Inc. (NCE), of Bothell, Wa., for $22.4 million. AMRI will also assume about $600,000 of NCE's outstanding [...]

Albany Molecular Research (Albany, NY) says that it has completed its $30-million acquisition of New Chemical Entities (NCE; Bothell, WA) (CW Jan. 3, p. [...]

Two recent acquisitions involving local companies help show where the biotechnology industry is focused in 2001: late-stage drug development. Seattle-based Corixa Corp.'s acquisition of South San Francisco-based Coulter Pharmaceutical added [...]

ALBANY MOLECULAR RESEARCH (ALBANY, NY) says it will acquire New Chemical Entities (NCE; Bothell, WA), a privately held drug discovery company with expertise in biotechnology, for $22.4 million, including $600,000 [...]

Albany Molecular Research Inc. (Nasdaq: AMRI) is acquiring New Chemical Entities Inc., a privately held drug discovery company in Bothell, Wash. Albany Molecular will spend $22.4 million for the pharmaceutical [...]

Nycomed Amersham (Rensselaer, NY) has sold its fine chemicals plant at Rensselaer to Organichem (Rensselaer), a buyout company group comprising former Nycomed managers and Albany Molecular Research (AMR; Albany, NY). [...]

Albany Molecular Research (Albany, NY) has completed its acquisition of EnzyMed, a developer of combinatorial biocatalysis for drug discovery. EnzyMed will remain an independent business unit. Albany Molecular is a [...]

ALBANY MOLECULAR Research Inc. (AMRI) is acquiring EnzyMed Inc., Iowa City, Iowa, a privately held drug discovery company that uses combinatorial biocatalysis, in a deal valued at nearly $20.6 million. [...]

Custom synthesis firm Albany Molecular Research (Albany, NY) will purchase contract R&D firm EnzyMed (Iowa City) for $20.6 million. 'The acquisition will allow our customers to create new drug molecules [...]

Albany Molecular Research Inc. (AMRI) announced that it has acquired all the outstanding equity interests of Whitehouse Laboratories for $54 million in cash, and an additional $2 million in shares [...]

AMRI (Albany, NY) acquired Excelsyn (Holywell, Wales), a provider of chemical development and large-scale manufacturing services to the pharmaceutical and biotechnology industries in Europe, Asia, and North America. Excelsyn's manufacturing [...]

Two leaders in the pharmaceutical industry have further expanded their operations in India - with Aptuit closing a drug development joint venture with Laurus Laboratories, and Albany Molecular Research Inc. acquiring Ariane Orgachem and Ferico Laboratories from the Runwal group for apprioximately 8 million euros. Ongoing and future operations of these US-based companies in India are also discussed.

Albany Molecular Research Inc. (AMRI; Albany, NY), a drug discovery and pharmaceutical manufacturing company, says it will acquire pharmaceutical manufacturing facilities at Aurangabad and Navi Mumbai in western India. AMRI [...]

Albany Molecular Research (AMRI) says it has agreed to acquire ComGenex (Budapest), a privately owned drug discovery service company, for an undisclosed sum. ComGenex has annual sales of about $8.5 [...]

Albany based drug discovery firm Albany Molecular Research Inc., has acquired Budapest based ComGenex Inc., for 11 million dollars. This acquisition is expected to increase the company's presence and revenue in Europe.

In a step toward the full acquisition of the company, Albany Molecular Research Inc. has purchased a majority interest in Organichem Corp. The company has exercised its conversion option with [...]

Contract drug research firm Albany Molecular Research has confirmed CW's report that it would increase its stake in contract drug intermediates manufacturer Organichem (Rensselaer, NY) (CW, Sept. 11, 2002, p. [...]

ALBANY MOLECULAR Research Inc. has increased its stake in Organichem Corp. from 39.2 to 75 percent, with plans to acquire the remainder within the next few months. The move completes [...]

Albany Molecular Research is likely to exercise its option this year to purchase the 60% of Organichem (Rensselear, NY) that it does not already own, says Donald Kuhla, president and [...]

Albany Molecular Research, Inc. (Albany, NY) has completed the purchase of Great Lakes Chemical Corporation's laboratory facilities in Mt. Prospect, [...]